Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Think Research Corporation (THKKF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.45000.0000 (0.00%)
At close: 9:33AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4500
Open1.4500
BidN/A x N/A
AskN/A x N/A
Day's Range1.4500 - 1.4500
52 Week Range1.4500 - 1.9017
Volume427
Avg. Volume33
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Think Research Announces Changes to Management Team

    Think Research Corporation (TSXV: THNK) ("Think" or the "Company"), a company focused on transforming healthcare through digital health software solutions, today announced changes to its management team to support the Company's strategic plans for continued growth. As part of these changes, the Company concluded a strategic review and has streamlined management layers reducing five management positions. Material cost reductions have been achieved as a result. As part of the review, Think has als

  • CNW Group

    Think Research Announces Change of Auditor to Ernst & Young LLP

    Think Research Corporation (TSXV: THNK) ("Think" or the "Company"), a company focused on transforming healthcare through digital health software solutions, today announced that it has changed its auditor from MNP LLP (the "Former Auditor") to Ernst & Young LLP (the "Successor Auditor") effective September 14, 2021 (the "Effective Date").

  • CNW Group

    Think Research Announces Shares for Services Arrangements with BioPharma Personnel

    Think Research Corporation (TSXV: THNK) ("Think" or the "Company"), a company focused on transforming healthcare through digital health software solutions, announced today that it has entered into shares for services arrangements with: (a) Mr. Renzo DiCarlo ("DiCarlo"), President, Clinical Research of Bio Pharma Services Inc. ("BioPharma"); and (b) four other key employees and contractors of BioPharma (collectively, the "Key Personnel").

Advertisement
Advertisement